Tempest Therapeutic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tempest Therapeutics : Corporate Presentation - June 2024

Tempest Therapeutics : Corporate Presentation - June 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Exchange commission onTempest therapeutics incSecurities actTempest therapeuticsTempest therapeuticExchange commission

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesStephen bradyAljanae reynoldsSylvia wheelerExchange commissionSociety for immunotherapy of cancerAmerican association for cancer researchCompany quarterly report on formSecurities exchangeTempest therapeutics incCancer prevention clinical trials networkNational cancer instituteJournal of cancer research communicationsDivision of cancer preventionCancer researchScientific meeting

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

BRISBANE, Calif., April 09, 2024 Tempest Therapeutics, Inc. , a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today.

United statesSylvia wheelerSam whitingAljanae reynoldsExchange commission onAmerican association for cancer researchExchange commissionSecurities exchangeBeth israel deaconess medical centerTempest therapeutics incHavard medicalAmerican associationCancer researchAnnual meetingSecurities exchange actSecurities act

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data,.

United statesSylvia wheelerAljanae reynoldsSam whitingCancer research communicationsExchange commission onSecurities exchangeExchange commissionTempest therapeutics incHuman phasei trialAdvanced solid tumorsSecurities exchange actSecurities actTempest therapeuticsTempest therapeutic

Tempest Therapeutics : Corporate Presentation - April 2024 -March 29, 2024 at 06:46 pm EDT

Company Overview April 2024 Forward-Looking Statements This presentation contains forward-looking statements.

Dipak panigrahyCompany overviewData support clinical development strategyExchange commissionTempest therapeutics incSecurities actTempest therapeuticsTempest therapeuticFirst in class oncology pipelineDependent tumors inform clinicalCatenin pathway inducesSupport clinical development